Table 2.
Asthma characteristics according to investigator-classified asthma severity in the SABINA III Turkey Cohort
| All (N = 579) | Patients classified by asthma severity (n = 568)* | ||
|---|---|---|---|
| Investigator-classified mild asthma (n = 98) | Investigator-classified moderate-to-severe asthma (n = 470) | ||
| Asthma duration (years) | |||
| Mean (SD) | 12.0 (9.9) | 8.6 (7.7) | 12.6 (10.2) |
| Median (min, max) | 9.0 (1.0, 56.0) | 6.0 (1.0, 40.0) | 10.0 (1.0, 56.0) |
| Number of severe asthma exacerbations 12 months before the study visit | |||
| Mean (SD) | 1.2 (1.8) | 0.3 (0.8) | 1.3 (1.9) |
| Number of severe asthma exacerbations 12 months before the study visit by group, n (%) | |||
| 0 | 310 (53.5) | 81 (82.7) | 223 (47.4) |
| 1 | 105 (18.1) | 8 (8.2) | 96 (20.4) |
| 2 | 61 (10.5) | 6 (6.1) | 53 (11.3) |
| 3 | 48 (8.3) | 2 (2.0) | 46 (9.8) |
| > 3 | 55 (9.5) | 1 (1.0) | 52 (11.1) |
| GINA classification, n (%) | |||
| Step 1 | 39 (6.7) | 39 (39.8) | 0 (0.0) |
| Step 2 | 60 (10.4) | 59 (60.2) | 0 (0.0) |
| Step 3 | 108 (18.7) | 0 (0.0) | 105 (22.3) |
| Step 4 | 187 (32.3) | 0 (0.0) | 184 (39.1) |
| Step 5 | 185 (32.0) | 0 (0.0) | 181 (38.5) |
| Level of asthma symptom control, n (%) | |||
| Well controlled | 253 (43.7) | 66 (67.3) | 182 (38.7) |
| Partly controlled | 188 (32.5) | 25 (25.5) | 159 (33.8) |
| Uncontrolled | 138 (23.8) | 7 (7.1) | 129 (27.4) |
| Number of comorbidities, n (%) | |||
| None | 191 (33.0) | 47 (48.0) | 142 (30.2) |
| 1–2 | 300 (51.8) | 36 (36.7) | 258 (54.9) |
| 3–4 | 78 (13.5) | 14 (14.3) | 61 (13.0) |
| ≥ 5 | 10 (1.7) | 1 (1.0) | 9 (1.9) |
GINA, Global Initiative for Asthma; max, maximum; min, minimum; SABINA, SABA use IN Asthma; SD, standard deviation
*Asthma severity data are reported for 568 patients and not for the six patients with missing data or the five patients erroneously categorised under primary care